New Delhi, February 10 Syngene International announced on Tuesday that it has entered into a partnership with Johns Hopkins University to advance early-stage drug discovery programs and platform technologies emerging from the university's research labs.
The collaboration will be delivered by Syngene SynVent, a fully integrated drug discovery and development platform that spans discovery biology, medicinal and synthetic chemistry, DMPK (Drug Metabolism and Pharmacokinetics), toxicology, and early development, the company said in a statement.
"We are uniquely positioned to translate pioneering research into credible therapeutic candidates, and our goal is to significantly reduce the time required for high-potential programs to become clinically relevant, creating a faster and more efficient pipeline of new medicines," said Kenneth Barr, Head of Strategic Collaborations at Syngene International.
Paul Nkansah, Senior Director of Corporate Partnerships at Johns Hopkins Technology Ventures, said that the collaboration model has the potential to link discoveries from Johns Hopkins laboratories with the drug discovery capabilities of Syngene, pharmaceutical and biotech partners, and investors.